⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EBS News
Emergent Biosolutions, Inc.
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
EBS
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
globenewswire.com
EBS
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
globenewswire.com
EBS
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
globenewswire.com
EBS
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
globenewswire.com
EBS
Vaccine Contract Manufacturing Market to Reach US$11,065.6 Million by 2036, as Immunisation Expansion and Rising Manufacturing Complexity Drive Outsourcing
globenewswire.com
EBS
Blood Plasma Derivatives Market to Reach USD 47.85 Billion by 2032 with a CAGR of 6.77%
globenewswire.com
EBS
GRFS
EBSCO Information Services Unveils Music Index Archive, Completing Its Trio of Music Research Resources
prnewswire.com
EBS
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
globenewswire.com
EBS
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
globenewswire.com
EBS